Currently Enrolling Trials
Zofran (Ondansetron) is a 5-HT3 receptor antagonist.
Zofran is approved for
- nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m2 .
- nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. (
- nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen
- postoperative nausea and/or vomiting
An intramuscular administration of Zofran for postoperative nausea and vomiting in adults has been approved by the FDA. Normally, Zofran is given through an IV injection or in tablet form. This new intramuscular (IM) administration bypasses difficulties some patients may encounter. For example, some patients have difficulty swallowing, have small veins, or have veins that won't allow an IV to enter.
While IM administration has been approved in adults, it has not gained clearance for use in children.
Negative side effects have been noted in postoperative clinical tests The most common are dizziness, headache, drowsiness, sedation, and constipation. Other adverse effects are diarrhea, dry mouth, and skin rash.